Drugs / MDV9300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01952769 | Feb 2014 → Nov 2018 | diffuse intrinsic pontine glioma | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02653989 | Dec 2016 → Jun 2018 | primary mediastinal large B-cell lymphoma | Medivation, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDV9300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653989 ↗ |
| Route | Intravenous | “MDV9300 was administered at 3 mg/kg IV every 4 weeks” NCT01952769 ↗ |